Efficacy of Invariant Natural Killer T Cell Infusion Plus Transarterial Embolization vs Transarterial Embolization Alone for Hepatocellular Carcinoma Patients: A Phase 2 Randomized Clinical Trial

Abstract

Jia Guo,1 Xuli Bao,1 Fuquan Liu,2 Jiang Guo,3 Yifan Wu,2 Fang Xiong,1 Jun Lu1 1Hepatology and Cancer Biotherapy Ward, Beijing YouAn Hospital, Capital Medical University, Beijing, People’s Republic of China; 2Department of Interventional Therapy, Beijing Shijitan Hospital, Capital Medical University, Beijing, People’s Republic of China; 3Department of Interventional Therapy, Beijing Ditan Hospital, Capital Medical University, Beijing, People’s Republic of ChinaCorrespondence: Jun Lu, Hepatology and Cancer Biotherapy Ward, Beijing YouAn Hospital, Capital Medical University, No. 8, Xi Tou Tiao, Youan Men Wai, Fengtai District, Beijing, 10069, People’s Republic of China, Tel [phone], Fax [phone], Email [email protected]: Invariant NKT cells (iNKT) are CD1d-restricted T cells with the capacity of antitumor immunity. The safety of autologous iNKT cell treatment in hepatocellular carcinoma (HCC) has been verified. This study aimed to investigate its efficacy in advanced HCC after transarterial chemoembolization (TACE) failure.Patients and methods: This open-label, randomized, controlled, trial enrolled 60 patients with unresectable HCC after TACE failure at three centers. Transarterial embolization (TAE) was used instead of TACE to protect iNKT cell function. Patients were randomly assigned (1:1) to receive TAE therapy with (TAE–iNKT) or without (TAE) biweekly iNKT cell infusion. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS), objective response rate (ORR), disease control rate (DCR), quality of life (QoL), peripheral blood cell count, and safety.Results: Fifty-four patients completed the study. Median PFS was significantly higher in TAE–iNKT patients (5.7 months [95% CI, 4.3– 7.0 months]) compared with TAE patients (2.7 months [95% CI, 2.3– 3.2 months]; hazard ratio 0.32 [95% CI, 0.16– 0.63]; P< 0.001). Higher ORR and DCR were observed in TAE–iNKT patients (52% and 85%, respectively) compared with TAE patients (11% and 33%; respectively). Five TAE–iNKT patients and 1 TAE patient achieved completed response. The median time to deterioration in QoL was longer in TAE–iNKT patients (9.2 months [95% CI, 6.0– 13.3 months]) compared with TAE patients (3.0 months [95% CI, 2.9– 3.0 months]). The mean lymphocytes were higher in the TAE-iNKT group than in the TAE group at 8 (1.48 vs 0.95× 109/L, P = 0.007) and 12 (1.49 vs 0.89× 109/L, P = 0.001) weeks. Grade 3 adverse events occurred in 1 TAE-iNKT patient (4%) and 5 TAE patients (19%). All the other adverse events were grade 1– 2.Conclusion: iNKT cell infusion significantly improved PFS, ORR, DCR, and QoL with manageable toxicity during TAE therapy in patients with HCC. Trial Registration ClinicalTrials.gov Identifier: NCT04011033.Keywords: hepatocellular carcinoma, invariant natural killer T cell, transarterial embolization, progression-free survival

Keywords

• hepatocellular carcinoma
• invariant natural killer t cell
• transarterial embolization
• progression-free survival